Biofrontera Bioscience GmbH

Quick facts

Phase 3 pipeline

• Placebo to BF-200 ALA gel · Dermatology/Oncology
  BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.

Phase 2 pipeline

• BF-200 ALA 1% · Dermatology
  BF-200 ALA 1% is a topical photosensitizer that, when activated by light, generates reactive oxygen species to induce cell death in targeted tissues.
• BF-200 ALA 10% · Dermatology/Oncology
  BF-200 ALA is a topical 5-aminolevulinic acid (ALA) formulation that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
• BF-200 ALA 3% · Dermatology
  BF-200 ALA 3% is a topical cream used to treat actinic keratosis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biofrontera Bioscience GmbH portfolio CI brief
• Biofrontera Bioscience GmbH pipeline updates RSS